Swiss pharma major Novartis is sharpening its strategy in India as a pure-play innovator across core therapy segments, including cardiovascular, oncology, and immunology. The company is moving further up the value chain in India, with early scientific discovery and Phase I studies beginning to take shape.
Novartis seeks to deepen India innovation play
You May Also Like
Posted in
All
CCI to probe Pernod Ricard, seven others
Posted by
avianscape.enterprises@gmail.com
Posted in
All
Loans outrun deposits, margins dip
Posted by
avianscape.enterprises@gmail.com